Cardiotoxicity induced by tyrosine kinase inhibitors

Acta Oncologica

Volumn 48, Issue 7, 2009, Pages 964-970

  Orphanos, George S ^a   Ioannidis, George N ^b   Ardavanis, Alexandros G ^c  

^a Ygia Polyclinic ^*  (Cyprus)

^b NICOSIA GENERAL HOSPITAL   (Cyprus)

^c SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ACUTE CORONARY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DERMATOFIBROSARCOMA PROTUBERANS; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; EOSINOPHILIC LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MORBIDITY; NONHUMAN; PANCREAS CANCER; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG MONITORING; HEART DISEASES; HUMANS; INCIDENCE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SEVERITY OF ILLNESS INDEX;

EID: 70350072838     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860903229124     Document Type: Review

References (40)

1. van der Geer P, Hunter T, Lindberg RA. Receptor proteintyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994;/10:/251.
2. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;/355:/172-87.
3. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;/8:/935-42.
4. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;/12:/908-16.
5. Khan MA. Effects of myotoxins on skeletal muscle fibers. Prog Neurobiol 1995;/46:/541-60.
6. Sanders EJ, Wride MA. Ultrastructural identification of apoptotic nuclei using the TUNEL technique. Histochem J 1996;/28:/275-81.
7. Dick JR, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: Enemy or ally? J Physiol 2006;/ 574:/95-112.
8. Steinberg SF. Distinctive activation mechanisms and functions for protein kinase C delta. Biochem J 2004;/384:/ 449-459
9. Perik PJ, Rikhof B, de Jong FA, Verweij J, Gietema JA, van der Graaf WT. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 2008;/19:/359-61.
10. Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 2006;/243:/16-22.
11. Tiribelli M, Colatutto A, Marin L, Barbina G, Qualizza U, Damiani D, et al. Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy. Am J Hematol 2008;/83:/517-8.
12. Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007;/43:/974-8.
13. O Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;/348:/994-1004. (Pubitemid 36302244)
14. Li B, Wang X, Rasheed N, Hu Y, Boast S, Ishii T, et al. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev 2004;/18:/ 1824-1837
15. Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007;/117:/4044-54.
16. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M, et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 2002;/277:/10244-50.
17. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;/305(5682):/399-401.
18. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007;/ 109:/5143-50. (Pubitemid 46890528)
19. Talpaz M, Shah N, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;/ 354:/2531-41. (Pubitemid 43882349)
20. Quintas-Cardama A, Cortes J. Nilotinib therapy in chronic myelogenous leukemia. Drugs Today 2007;/43:/691-702. (Pubitemid 350220793)
21. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;/368(9544):/1329-1338.
22. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;/ 356:/115-24. (Pubitemid 46089672)
23. Chu TF, RupnickMA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;/370(9604):/2011-9.
24. Hsieh PC, MacGillvray C, Gannon J, Cruz FU, Lee RT. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006;/114:/637-44.
25. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;/112:/2500-8.
26. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008;/19:/1613-8.
27. Van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;/99:/259-65.
28. Bayer Pharmaceuticals. Nexavar (sorafenib) prescribing information: 2009. Available from: http://www.univgraph. com/bayer/inserts/nexavar.pdf
29. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;/12:/426-37.
30. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;/356:/125-34.
31. Sablin MP, Bouaita L, Balleguier C, Gautier J, Celier C, Balcaceres JL, et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 2007;25(18 Suppl)5038 (Abstract).
32. Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol 2007;/18:/1906-7.
33. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;/26:/5204-12.
34. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007;/12:/ 191-200. (Pubitemid 46271621)
35. Muslin AJ. Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc Med 2005;/15:/ 225-229
36. Yamaguchi O, Watanabe T, Nishida K, Kashiwase K, Higuchi Y, Takeda T, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004;/114:/937-43.
37. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;/115:/2108-2118.
38. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006;/355:/ 2733-2743
39. Burris HA. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004;/9(Suppl 3):/10-5.
40. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;/304 (5676):/1497-500.